Scleroderma laboratory findings: Difference between revisions
Created page with "__NOTOC__ {{Scleroderma}} {{CMG}} ==Overview== ==Laboratory Findings== Diagnosis is by clinical suspicion, presence of autoantibodies (specifically [[anti-centromere antibo..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Scleroderma}} | {{Scleroderma}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
Diagnosis is by clinical suspicion, presence of autoantibodies (specifically [[anti-centromere antibodies|anti-centromere]] and anti-scl70/[[anti-topoisomerase antibodies]]) and occasionally by biopsy. Of the antibodies, 90% have a detectable [[anti-nuclear antibody]]. Anti-centromere antibody is more common in the limited form (80-90%) than in the systemic form (10%), and anti-scl70 is more common in the diffuse form (30-40%) and in African-American patients (who are more susceptible to the systemic form).<ref name=JimenezDerk>{{cite journal |author=Jimenez SA, Derk CT |title=Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis |journal=Ann. Intern. Med. |volume=140 |issue=1 |pages=37-50 |year=2004 |pmid=14706971 |doi=}}</ref> | Diagnosis is by clinical suspicion, presence of autoantibodies (specifically [[anti-centromere antibodies|anti-centromere]] and anti-scl70/[[anti-topoisomerase antibodies]]) and occasionally by biopsy. Of the antibodies, 90% have a detectable [[anti-nuclear antibody]]. Anti-centromere antibody is more common in the limited form (80-90%) than in the systemic form (10%), and anti-scl70 is more common in the diffuse form (30-40%) and in African-American patients (who are more susceptible to the systemic form).<ref name=JimenezDerk>{{cite journal |author=Jimenez SA, Derk CT |title=Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis |journal=Ann. Intern. Med. |volume=140 |issue=1 |pages=37-50 |year=2004 |pmid=14706971 |doi=}}</ref> | ||
| Line 11: | Line 9: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Autoimmune diseases]] | |||
[[Category:Diseases involving the fasciae]] | |||
[[Category:Rheumatology]] | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 21:15, 7 November 2012
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Scleroderma laboratory findings |
|
Risk calculators and risk factors for Scleroderma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
Diagnosis is by clinical suspicion, presence of autoantibodies (specifically anti-centromere and anti-scl70/anti-topoisomerase antibodies) and occasionally by biopsy. Of the antibodies, 90% have a detectable anti-nuclear antibody. Anti-centromere antibody is more common in the limited form (80-90%) than in the systemic form (10%), and anti-scl70 is more common in the diffuse form (30-40%) and in African-American patients (who are more susceptible to the systemic form).[1]